Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.

Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. Clin Cancer Res. 2015 Oct 01; 21(19):4321-6.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Non-Small-Cell Lung
ErbB Receptors
Erlotinib Hydrochloride
Female
Heterocyclic Compounds, 3-Ring
Humans
Kaplan-Meier Estimate
Lung Neoplasms
Male
Middle Aged
Neoplasm Staging
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-akt
Retreatment
Treatment Outcome

authors with profiles

Ravi Salgia